This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D61.9 | Synonyms: hypoplastic anemia (unspecified), Hypoplastic anaemia unspecified, aplastic anemia, unspecified
Hypoplastic anaemia is a general term for conditions in which bone marrow cellularity is reduced and red blood cell production is decreased, reflecting mild to moderate states within the spectrum of complete marrow aplasia (aplastic anaemia). The classification 'NOS (Not Otherwise Specified)' includes cases in which the cause has not been clearly identified or that do not fit a specific subtype.
With the introduction of bone marrow biopsy techniques into clinical practice in the 1950s–1960s, it became possible to quantitatively assess reduced marrow cellularity. Later, when Camitta et al. (1976) proposed classification criteria for severe aplastic anemia, the boundary between hypoplasia and aplasia became clearer. In the ICD classification system, the NOS code is used to cover cases not classified into a specific subtype.
D61.9 is "aplastic anaemia, unspecified", and hypoplastic anemia NOS is included in this code. It is applied when diagnostic workup is incomplete and a specific subtype cannot be confirmed, or when a rare form of bone marrow failure does not fit a specific classification.
The most common situation in hypoplastic anemia NOS is idiopathic, with no clear cause found. In these cases, an autoimmune mechanism is presumed to underlie most of them.
Chloramphenicol (the most representative), sulfonamides, anticonvulsants (phenytoin, carbamazepine), antirheumatic drugs (gold compounds, D-penicillamine), NSAIDs, antithyroid drugs, etc. can cause hypoplastic anemia. There are two mechanisms: dose-dependent toxicity and idiosyncratic reaction.
Parvovirus B19 specifically infects erythroid precursor cells (erythroblasts), causing transient or chronic pure red cell aplasia (PRCA). In immunodeficient patients, chronic parvovirus B19 infection is a cause of persistent hypoplastic anemia.
Folate, vitamin B12, and copper deficiencies cause impaired maturation of hematopoietic precursors and may show findings resembling hypoplastic anemia. Hypoplastic anemia associated with autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and Sjögren syndrome may occur.
Hypoplastic anemia NOS is not a monogenic disease and mostly arises from multifactorial or acquired mechanisms. Overrepresentation of the HLA-DRB1*15:01, HLA-DRB1*15:02 alleles is observed in some patients. Somatic mutations in DNMT3A, TET2, ASXL1, U2AF1, etc. found by NGS may suggest overlap with MDS or clonal hematopoiesis (CHIP).
Small PNH clones (PIGA mutations) are found in some patients with hypoplastic anemia NOS, which is evidence supporting an immune mechanism for hypoplastic anemia.
There are no separate incidence statistics for hypoplastic anemia NOS; it is reported within the category of aplastic anemia, unspecified (D61.9). The annual incidence of aplastic anemia overall is 2–3 per 1,000,000 in Western countries and 5–7 per 1,000,000 in East Asia, and hypoplastic anemia NOS, as a subcategory, includes cases without a clearly identified cause.
The sex and age distribution is similar to that of aplastic anemia overall. In children, inherited causes (DBA, Fanconi anemia) or transient erythroblastopenia are common, while in adults acquired autoimmune mechanisms predominate.
In Korea, hypoplastic anemia NOS is mainly applied to cases of bone marrow failure in which the exact cause has not been identified. As accurate diagnostic techniques have improved with the development of medical infrastructure, the proportion classified as NOS is decreasing.
The core mechanism of hypoplastic anemia is a reduction in the number and function of erythroid precursors (BFU-E, CFU-E, erythroblasts). In global marrow hypoplasia, not only erythroid but also myeloid and megakaryocytic precursors are reduced, accompanied by pancytopenia.
Autoreactive T cells and inhibitory cytokines such as IFN-γ and TNF-α suppress the proliferation and differentiation of erythroid precursors. Large granular lymphocyte (LGL)-mediated cytotoxicity can selectively destroy marrow precursors.
Parvovirus B19 uses globoside (P antigen) as its receptor and specifically infects CFU-E and proerythroblasts. Viral replication causes cell lysis, resulting in transient (TEC) or chronic (in immunodeficiency) pure red cell aplasia.
In some hypoplastic anemias, abnormal erythropoietin (EPO) receptor signaling or reduced EPO responsiveness of precursors has been reported. In DBA, translational stress due to ribosomal protein abnormalities induces specific apoptosis of erythroid precursors.
The main symptoms are fatigue, lethargy, headache, dizziness, pallor, exertional dyspnea, and palpitations. The severity of symptoms is determined by the degree of anemia.
In global marrow hypoplasia, susceptibility to infection due to leukopenia and thrombocytopenia, and a bleeding tendency (petechiae, gum bleeding, nosebleeds) additionally appear.
PRCA is characterized by selective reduction of only the erythroid lineage, so only anemia symptoms appear, without infection or bleeding tendency. In transient erythroblastopenia of childhood, sudden anemia develops within days to weeks after a fever.
Pallor (conjunctival, oral mucosal, palmar pallor) is the main physical sign. With severe anemia, tachycardia and a systolic murmur may appear. With accompanying pancytopenia, petechiae, purpura, and oral ulcers are observed.
Normocytic normochromic anaemia or macrocytic anemia is characteristic. The reticulocyte count is markedly decreased in absolute terms (<20,000/μL). In global marrow hypoplasia, leukopenia and thrombocytopenia accompany it.
| Subtype | Type of cytopenia | Bone marrow findings | Specific tests |
|---|---|---|---|
| Hypoplastic aplastic anemia | Pancytopenia | Reduced cellularity, reduction of all lineages | PNH clone, HLA |
| Pure red cell aplasia (PRCA) | Anemia only (WBC, PLT normal) | Selective reduction of erythroblasts (<1%) | Parvovirus B19 PCR, chest CT (thymoma) |
| Diamond-Blackfan anemia (DBA) | Anemia only | Reduced erythroid precursors | eADA activity, RPS19 variant |
| Transient erythroblastopenia of childhood (TEC) | Transient anemia | Transient reduction of erythroblasts | Confirmation of spontaneous recovery |
Hypoplastic anemia is suspected in unexplained anemia, especially anemia with reduced reticulocytes. CBC, reticulocyte count, and peripheral blood smear are the initial screening.
Exclusion of nutritional deficiencies (vitamin B12, folate, iron, copper); renal function assessment (exclusion of renal anemia); thyroid function tests; autoimmune markers (SLE, etc.); viral serology (parvovirus B19, EBV, CMV, hepatitis viruses).
When DBA is suspected in children, measurement of erythrocyte adenosine deaminase (eADA) activity and genetic testing such as RPS19. DEB/MMC chromosomal fragility testing to exclude Fanconi anemia.
Hypoplastic anemia NOS is diagnosed when the following conditions are met: ① persistent anemia (decreased Hb); ② decreased absolute reticulocyte count; ③ reduced marrow cellularity or selective reduction of erythroid precursors on bone marrow biopsy; ④ minimal or no dysplasia; ⑤ not fully meeting the criteria for a specific subtype.
Pure red cell aplasia is diagnosed when erythroblasts are <1% on bone marrow biopsy and white blood cells and platelets are normal. To identify the cause, parvovirus B19 PCR, thymoma workup (chest CT), LGL analysis, and autoantibody testing are performed.
Diamond-Blackfan anemia is diagnosed by ① onset within the first year of life ② normocytic anemia ③ reduced reticulocytes ④ selective reduction of erythroid precursors in the marrow ⑤ elevated erythrocyte adenosine deaminase (eADA) activity ⑥ confirmation of a ribosomal gene variant.
In hypoplastic anemia NOS, treatment of the cause comes first. In drug-induced cases, the causative drug is discontinued. In parvovirus B19-associated PRCA, immunodeficient patients are given intravenous immunoglobulin (IVIG). In nutritional deficiencies, the relevant nutrient is supplemented.
Packed red blood cell transfusion is given when Hb <7 g/dL or when symptomatic. In chronically transfusion-dependent patients, iron overload is prevented with iron chelation therapy. Transfusion is supportive therapy, not definitive treatment.
In hypoplastic anemia due to an autoimmune mechanism, immunosuppressive therapy such as corticosteroids (especially some PRCA, DBA), cyclosporine A, and ATG may be tried. In severe or refractory hypoplastic anemia, allogeneic HSCT is considered when an HLA-matched donor is available. In DBA, HSCT is effective when the disease is corticosteroid-refractory or transfusion dependence is severe.
In chronic transfusion-dependent hypoplastic anemia, iron overload (damage to the heart, liver, and endocrine organs) has an important effect on long-term prognosis. The risk of clonal evolution (MDS, AML) is monitored regularly.
When using marrow-toxic drugs, unnecessary long-term administration is avoided and blood counts are monitored regularly. Chloramphenicol is replaced with alternative antibiotics whenever possible. Early recognition of idiosyncratic drug reactions is important.
In immunodeficient patients, the risk of infections such as parvovirus B19 is monitored. Participation in vaccination programs lowers the risk of viral infection. In patients diagnosed with hypoplastic anemia, worsening and clonal evolution are detected early through regular CBC follow-up, and iron overload monitoring and iron chelation therapy are performed in chronically transfusion-dependent patients.